Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shenzhen Neptunus Interlong Bio-Technique Co Altman Z-Score?
Shenzhen Neptunus Interlong Bio-Technique CoHKSE:08329 -5.71% Altman Z-Score is 1.46 as of Sep. 16, 2026, which is 39% below its 10-year median of 2.40. The stock has 3 warning signs investors should review. Among 954 Drug Manufacturers companies, Shenzhen Neptunus Interlong Bio-Technique Co ranks worse than 76% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.48 is in distress zone. This implies bankruptcy possibility in the next two years.
Shenzhen Neptunus Interlong Bio-Technique Co has a Altman Z-Score of 1.46, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co Altman Z-Score Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Altman Z-Score vs Drug Manufacturers Industry
Shenzhen Neptunus Interlong Bio-Technique Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Altman Z-Score of 1.46 as of Sep. 16, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 39% below median its historical median of 2.40. Over the past decade, Shenzhen Neptunus Interlong Bio-Technique Co's Altman Z-Score has ranged from 1.48 to 3.39. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #725 out of 954 companies in the Drug Manufacturers industry, placing it in the top 76%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Altman Z-Score too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Altman Z-Score of 1.46 is 39% below median its 10-year median of 2.40. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 3.39. The Drug Manufacturers industry median Altman Z-Score is 3.36. Shenzhen Neptunus Interlong Bio-Technique Co's value of 1.46 is 56.5% below this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #725 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Altman Z-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #725 out of 954 companies for Altman Z-Score. This places Shenzhen Neptunus Interlong Bio-Technique Co in the lower half of its industry. The industry median Altman Z-Score is 3.36. Shenzhen Neptunus Interlong Bio-Technique Co's value of 1.46 is 56.5% below this benchmark. Historically, Shenzhen Neptunus Interlong Bio-Technique Co's own Altman Z-Score has ranged from 1.48 to 3.39 over the past decade. While the company's 10-year median is 2.40 vs. the industry median of 3.36, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.36, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current Altman Z-Score of 1.46 is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Altman Z-Score is 1.46, which is 39% below median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current Altman Z-Score is 1.46, which is 39% below median its 10-year median of 2.40 and 56.5% below the Drug Manufacturers industry median of 3.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Altman Z-Score is 1.46 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
